Journal: Biomedicines

Article Title: Hippocampal Leptin Resistance and Cognitive Decline: Mechanisms, Therapeutic Strategies and Clinical Implications

doi: 10.3390/biomedicines12112422

Figure Lengend Snippet: Ongoing clinical trials in obesity and/or overweight using amylin analogs or Celastrol (up to 16 October 2024).

Article Snippet: 7 , NCT00819234 II/RTBPC , Pramlintide (combined with Metreleptin) or placebo , Obesity , Measurement of the mean percentage of change in body weight from the baseline of the original study (NCT00673387) at week 52 in the extension study. , AstraZeneca , Completed , 15 April 2015.

Techniques: Clinical Proteomics, Drug discovery

Journal: Biomedicines

Article Title: Hippocampal Leptin Resistance and Cognitive Decline: Mechanisms, Therapeutic Strategies and Clinical Implications

doi: 10.3390/biomedicines12112422

Figure Lengend Snippet: Ongoing clinical trials in obesity and/or overweight using amylin analogs or Celastrol (up to 16 October 2024).

Article Snippet: 8 , NCT01235741 II/RDBPC , Pramlintide (combined with Metreleptin) or placebo , Obesity , Effect of 16 weeks of treatment on body weight in subjects with obesity. Studies of safety and tolerability of the drug combination. , AstraZeneca , Terminated , 15 April 2015.

Techniques: Clinical Proteomics, Drug discovery

Journal: Clinical pharmacology and therapeutics

Article Title: Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy

doi: 10.1038/clpt.2010.57

Figure Lengend Snippet: Centrally-Acting Anti-Obesity Drugs

Article Snippet: Phase II AgRP TTT-435 AgRP inhibitor TransTech Pharma Phase II MCH BMS-830216 MCH-1 receptor antagonist Bristol-Myers Squibb Phase I/II CCK GI 181771X Selective CCK-A agonist Glaxo Smith Kline Terminated GLP-1 Vildagliptin DDP-IV inhibitor Novartis Phase III Sitagliptin DDP-IV inhibitor Merck Approved for Diabetes Liraglutide Proteolysis resistant GLP-1 analogue Novo Nordisk Approved for Diabetes Exenatide Proteolysis resistant GLP-1 analogue Amylin/Eli Lilly Approved for Diabetes Exenatide-LAR Long-acting proteolysis resistant GLP-1 analogue Amylin/Eli Lilly FDA Regulatory Review NN9924 Long-acting oral GLP-1 analogue Novo Nordisk Phase I Oxyntomodulin (OXM) TKS1225 Long-acting OXM analogue Thiakis, Ltd./Wyeth/Pfizer Pre-Clinical PYY PYY (3–36) Intranasal active PYY Nastech/Merck Phase I/II Ghrelin NOX-B11 Ghrelin inactivator NOXXON Pharma Ag/Pfizer Pre-Clinical Oral Ghrelin Antagonist Ghrelin antagonist Elixir Pharmaceuticals Pre-Clinical Pancreatic polypeptide (PP) Obinepitide Y2/Y4 receptor agonist 7TM Pharma Phase I/II TM30339 Selective Y4 receptor agonist 7TM Pharma Phase I/II Amylin Pramlintide Synthetic amylin analogue Amylin Pharmaceuticals Approved for Diabetes Leptin Metreleptin/Pramlintide Leptin/amylin analogues Amylin Pharmaceuticals Phase II 5HT 2C Receptor Lorcaserin HCl 5HT 2C agonist Arena Pharmaceuticals, Inc. FDA Review H 1 /H 3 Receptor SCH-497079 H 3 receptor antagonist Schering-Plough Phase II Histalean H 1 -receptor agonist/H 3 receptor antagonist OBEcure, Ltd.

Techniques: Analogues